Trial · NCT04530188
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time course of extravascular lung water (EVLW) | Through study completion, up to 90 days | EVLW is the amount of water contained in the lungs outside the pulmonary vasculature. It can be measured using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Primary | Time course of pulmonary vascular permeability index (PVPI) | Through study completion, up to 90 days | PVPI is estimated using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Secondary | Value of extravascular lung water index (EVLW) | Day 2 | EVLW is the amount of water contained in the lungs outside the pulmonary vasculature. It can be measured using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Secondary | Value of extravascular lung water index (EVLW) | Day 5 | EVLW is the amount of water contained in the lungs outside the pulmonary vasculature. It can be measured using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Secondary | Value of pulmonary vascular permeability index (PVPI) | Day 2 | PVPI is estimated using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Secondary | Value of pulmonary vascular permeability index (PVPI) | Day 5 | PVPI is estimated using the transpulmonary thermodilution technique with the PiCCO2 device (Pulsion Medical Systems, Feldkirchen, Germany) |
| Secondary | Daily fluid balance | Through study completion, up to 90 days | Fluid balance will be calculated daily as fluid intake minus fluid output. It is expressed in mL/day. |
| Secondary | Need in catecholamines | Through study completion, up to 90 days | |
| Secondary | time between sedation cessation and first weaning trial | Through study completion, up to 90 days | |
| Secondary | Ventilator free days | Day 28 | ventilator-free days to taking into account death as a competing event |
| Secondary | Mortality | Day 28 | |
| Secondary | Oxygenation assessed with PaO2/FiO2 ratio | Day 2 | |
| Secondary | Oxygenation assessed with PaO2/FiO2 ratio | Day 5 | |
| Secondary | Oxygenation assessed with PaO2/FiO2 ratio | Through study completion, up to 90 days | |
| Secondary | Plasma and alveolar levels of proinflammatory cytokines : tumor necrosis factor alpha (TNFα, interleukin (IL)-1β, IL-6, IL-8 | At enrollment | Blood samples and alveolar samples from a bronchoalveolar lavage to constitute a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS |
| Secondary | Plasma and alveolar levels of proinflammatory cytokines : tumor necrosis factor alpha (TNFα, interleukin (IL)-1β, IL-6, IL-8 | Day 2 | Blood samples and alveolar samples from a bronchoalveolar lavage to constitute a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane on inflammation in patients with ARDS |
| Secondary | Plasma and alveolar levels of proinflammatory cytokines : tumor necrosis factor alpha (TNFα, interleukin (IL)-1β, IL-6, IL-8 | Day 5 | Blood samples and alveolar samples from a bronchoalveolar lavage to constitute a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane on inflammation in patients with ARDS |
| Secondary | Cardiac index | Through study completion, up to 90 days | Data provided by transpulmonary thermodilution. (unit: L/min/m2) |
| Secondary | Global End Diastolic Volume index | Through study completion, up to 90 days | Data provided by transpulmonary thermodilution. (unit: mL/m2) |
| Secondary | Blood pressure | Through study completion, up to 90 days | Systolic, diastolic and mean blood pressure |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04530188/registered